Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company's initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company's product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company's product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:EDGE
- CUSIP: N/A
- Web: www.edgetherapeutics.com
Capitalization:- Market Cap: $290.93 million
- Outstanding Shares: 30,851,000
Average Prices:- 50 Day Moving Avg: $10.38
- 200 Day Moving Avg: $9.87
- 52 Week Range: $7.30 - $13.50
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.51
- P/E Growth: -0.06
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $2.73 per share
- Price / Book: 3.49
Profitability:- EBIDTA: ($45,700,000.00)
- Return on Equity: -52.56%
- Return on Assets: -41.74%
Debt:- Debt-to-Equity Ratio: 0.20%
- Current Ratio: 9.43%
- Quick Ratio: 9.43%
Misc:- Average Volume: 80,320 shs.
- Beta: 2.71
- Short Ratio: 16.02
Frequently Asked Questions for Edge Therapeutics (NASDAQ:EDGE)
What is Edge Therapeutics' stock symbol?
Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE."
How were Edge Therapeutics' earnings last quarter?
Edge Therapeutics, Inc. (NASDAQ:EDGE) issued its quarterly earnings data on Tuesday, August, 1st. The company reported ($0.44) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.00. View Edge Therapeutics' Earnings History.
When will Edge Therapeutics make its next earnings announcement?
Where is Edge Therapeutics' stock going? Where will Edge Therapeutics' stock price be in 2017?
2 brokers have issued 1-year target prices for Edge Therapeutics' shares. Their forecasts range from $21.00 to $30.00. On average, they expect Edge Therapeutics' stock price to reach $25.50 in the next year. View Analyst Ratings for Edge Therapeutics.
Who are some of Edge Therapeutics' key competitors?
Some companies that are related to Edge Therapeutics include Sucampo Pharmaceuticals (SCMP), Calithera Biosciences (CALA), BioCryst Pharmaceuticals (BCRX), Aurinia Pharmaceuticals (AUPH), Karyopharm Therapeutics (KPTI), Achillion Pharmaceuticals (ACHN), CLEMENTIA PHARM (CMTA), Progenics Pharmaceuticals (PGNX), Jounce Therapeutics (JNCE), Atara Biotherapeutics (ATRA), NantKwest (NK), GlycoMimetics (GLYC), AVEO Pharmaceuticals (AVEO), Bellicum Pharmaceuticals (BLCM), UROGEN PHARMA (URGN), Selecta Biosciences (SELB), Mersana Therapeutics (MRSN) and Kura Oncology (KURA).
Who are Edge Therapeutics' key executives?
Edge Therapeutics' management team includes the folowing people:
- Sol J. Barer, Independent Chairman of the Board
- Brian A. Leuthner, President, Chief Executive Officer, Director
- Isaac Blech, Independent Vice Chairman of the Board
- Albert N. Marchio II, Interim Chief Financial Officer, Chief Accounting Officer, Chief Administrative Officer
- Daniel Brennan, Chief Operating Officer
- W. Bradford Middlekauff, Senior Vice President, General Counsel, Secretary
- Alyssa J. S. Wyant, Senior Vice President, Regulatory Affairs
- R. Loch Macdonald M.D. Ph.D., Chief Scientific Officer, Director
- Herbert J. Faleck, Chief Medical Officer
- Kurt G. Conti, Independent Director
Who owns Edge Therapeutics stock?
Edge Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (8.64%), Janus Henderson Group PLC (6.94%), VHCP Management II LLC (6.27%), Eagle Asset Management Inc. (2.92%), Vanguard Group Inc. (2.21%) and State Street Corp (0.90%). Company insiders that own Edge Therapeutics stock include Albert N Marchio II, Andrew J Einhorn, Brian A Leuthner, James Healy, James J Loughlin and W Bradford Middlekauff. View Institutional Ownership Trends for Edge Therapeutics.
Who sold Edge Therapeutics stock? Who is selling Edge Therapeutics stock?
Edge Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Vanguard Group Inc., JPMorgan Chase & Co., Bank of New York Mellon Corp, FMR LLC, Mark Sheptoff Financial Planning LLC, Regentatlantic Capital LLC and New York State Common Retirement Fund. Company insiders that have sold Edge Therapeutics stock in the last year include Albert N Marchio II and Brian A Leuthner. View Insider Buying and Selling for Edge Therapeutics.
Who bought Edge Therapeutics stock? Who is buying Edge Therapeutics stock?
Edge Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, State Street Corp, Goldman Sachs Group Inc., Franklin Resources Inc., SG Americas Securities LLC, DAFNA Capital Management LLC, State of Wisconsin Investment Board and Voya Investment Management LLC. Company insiders that have bought Edge Therapeutics stock in the last two years include Andrew J Einhorn, James Healy, James J Loughlin and W Bradford Middlekauff. View Insider Buying and Selling for Edge Therapeutics.
How do I buy Edge Therapeutics stock?
Shares of Edge Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Edge Therapeutics' stock price today?
One share of Edge Therapeutics stock can currently be purchased for approximately $9.52.
MarketBeat Community Rating for Edge Therapeutics (NASDAQ EDGE)MarketBeat's community ratings are surveys of what our community members think about Edge Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Edge Therapeutics (NASDAQ:EDGE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $25.50 (167.86% upside) |
Analysts' Ratings History for Edge Therapeutics (NASDAQ:EDGE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/3/2017 | Leerink Swann | Reiterated Rating | Outperform -> Outperform | $21.00 | N/A |  |
| 3/3/2017 | Guggenheim | Reiterated Rating | Buy -> In-Line | $30.00 | N/A | |
| 5/9/2016 | Credit Suisse Group | Lower Price Target | Outperform | $19.00 -> $18.00 | N/A | |
| 3/9/2016 | JMP Securities | Lower Price Target | Market Outperform | $34.00 -> $18.00 | N/A | |
(Data available from 9/20/2015 forward)
Earnings History for Edge Therapeutics (NASDAQ:EDGE)Earnings History by Quarter for Edge Therapeutics (NASDAQ EDGE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/30/2017 | | ($0.48) | | | | | N/A | |
| 8/1/2017 | Q2 2017 | ($0.44) | ($0.44) | | | View | Listen | |
| 5/3/2017 | Q1 2017 | ($0.42) | ($0.42) | | | View | Listen | |
| 3/2/2017 | Q4 2016 | ($0.42) | ($0.33) | | | View | Listen | |
| 8/3/2016 | Q2 | ($0.38) | ($0.33) | | | View | Listen | |
| 5/3/2016 | Q1 2016 | ($0.34) | ($0.32) | | | View | Listen | |
| 3/8/2016 | Q4 | ($0.32) | ($0.30) | | | View | Listen | |
| 11/6/2015 | Q315 | ($0.23) | ($7.08) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Edge Therapeutics (NASDAQ:EDGE)2017 EPS Consensus Estimate: ($1.89)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.42) | ($0.42) | ($0.42) |
| Q2 2017 | 1 | ($0.45) | ($0.45) | ($0.45) |
| Q3 2017 | 1 | ($0.48) | ($0.48) | ($0.48) |
| Q4 2017 | 1 | ($0.54) | ($0.54) | ($0.54) |
(Data provided by Zacks Investment Research)
Dividend History for Edge Therapeutics (NASDAQ:EDGE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Edge Therapeutics (NASDAQ:EDGE)Insider Ownership Percentage: 36.19%
Institutional Ownership Percentage: 49.38%
Insider Trades by Quarter for Edge Therapeutics (NASDAQ:EDGE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/6/2017 | Brian A Leuthner | Insider | Sell | 7,500 | $10.21 | $76,575.00 | |
| 9/5/2017 | Brian A Leuthner | CEO | Sell | 2,500 | $9.94 | $24,850.00 | |
| 9/1/2017 | Brian A Leuthner | CEO | Sell | 2,500 | $10.37 | $25,925.00 | |
| 8/29/2017 | Albert N Marchio II | Insider | Sell | 2,500 | $10.42 | $26,050.00 | |
| 8/23/2017 | Albert N Marchio II | Insider | Sell | 1,000 | $10.39 | $10,390.00 | |
| 8/3/2017 | Brian A Leuthner | Insider | Sell | 7,500 | $10.53 | $78,975.00 | |
| 7/6/2017 | Brian A Leuthner | Insider | Sell | 7,500 | $10.19 | $76,425.00 | |
| 3/6/2017 | James J Loughlin | Director | Buy | 3,000 | $9.24 | $27,720.00 | |
| 2/7/2017 | Brian A Leuthner | Insider | Sell | 1,500 | $9.52 | $14,280.00 | |
| 2/6/2017 | Brian A Leuthner | Insider | Sell | 3,000 | $9.61 | $28,830.00 | |
| 2/2/2017 | Brian A Leuthner | Insider | Sell | 3,000 | $9.50 | $28,500.00 | |
| 12/1/2016 | Brian A Leuthner | Insider | Sell | 7,500 | $11.60 | $87,000.00 | |
| 10/3/2016 | Brian A Leuthner | Insider | Sell | 7,500 | $10.25 | $76,875.00 | |
| 8/8/2016 | W Bradford Middlekauff | VP | Buy | 10,000 | $9.48 | $94,800.00 | |
| 8/1/2016 | Brian A Leuthner | Insider | Sell | 7,500 | $9.54 | $71,550.00 | |
| 3/11/2016 | James Healy | Director | Buy | 541,343 | $7.30 | $3,951,803.90 | |
| 10/6/2015 | Andrew J. Einhorn | CFO | Buy | 45,000 | $11.00 | $495,000.00 | |
| 10/6/2015 | James Healy | Director | Buy | 450,000 | $11.00 | $4,950,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Edge Therapeutics (NASDAQ:EDGE)
Latest Headlines for Edge Therapeutics (NASDAQ:EDGE)
| Source: |
|
| Date | Headline |
|---|
 | BRIEF-Edge Therapeutics appoints Rosemary Crane to Board of Directors
www.reuters.com - September 19 at 11:07 PM |
 | Edge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, to its Board of Directors
finance.yahoo.com - September 19 at 6:07 PM |
 | Leerink Swann Comments on Edge Therapeutics, Inc.'s FY2017 Earnings (EDGE)
www.americanbankingnews.com - September 8 at 6:50 AM |
| Insider Selling: Edge Therapeutics, Inc. (EDGE) CEO Sells 2,500 Shares of Stock
www.americanbankingnews.com - September 6 at 10:46 PM |
| Insider Selling: Edge Therapeutics, Inc. (EDGE) CEO Sells 2,500 Shares of Stock
www.americanbankingnews.com - September 6 at 10:46 PM |
| Edge Therapeutics, Inc. (EDGE) Insider Sells $76,575.00 in Stock
www.americanbankingnews.com - September 6 at 10:26 PM |
 | Navidea To Initiate Regular Webcast Series Featuring Moderated Q&A with Management
www.businesswire.com - August 30 at 7:19 PM |
| Edge Therapeutics, Inc. (EDGE) Insider Albert N. Marchio II Sells 2,500 Shares
www.americanbankingnews.com - August 29 at 8:24 PM |
| Zacks Investment Research Upgrades Edge Therapeutics, Inc. (EDGE) to "Hold"
www.americanbankingnews.com - August 29 at 7:38 PM |
| Zacks: Analysts Anticipate Edge Therapeutics, Inc. (EDGE) to Post -$0.48 EPS
www.americanbankingnews.com - August 24 at 10:24 PM |
| Insider Selling: Edge Therapeutics, Inc. (EDGE) Insider Sells 1,000 Shares of Stock
www.americanbankingnews.com - August 24 at 8:23 PM |
| Zacks: Edge Therapeutics, Inc. (NASDAQ:EDGE) Given Consensus Recommendation of "" by Analysts
www.americanbankingnews.com - August 8 at 6:24 PM |
| -$0.48 Earnings Per Share Expected for Edge Therapeutics, Inc. (EDGE) This Quarter
www.americanbankingnews.com - August 6 at 12:28 PM |
| Edge Therapeutics, Inc. (EDGE) Insider Brian A. Leuthner Sells 7,500 Shares
www.americanbankingnews.com - August 3 at 10:56 PM |
| Edge Therapeutics, Inc. (EDGE) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - August 3 at 7:20 PM |
| FY2018 EPS Estimates for Edge Therapeutics, Inc. (NASDAQ:EDGE) Lowered by Leerink Swann
www.americanbankingnews.com - August 3 at 3:32 PM |
| Edited Transcript of EDGE earnings conference call or presentation 1-Aug-17 12:30pm GMT
finance.yahoo.com - August 2 at 7:02 PM |
| Edge Therapeutics, Inc. (NASDAQ:EDGE) Posts Earnings Results, Hits Expectations
www.americanbankingnews.com - August 2 at 2:42 PM |
| Edge Therapeutics Reports Second Quarter 2017 Financial Results and Continued Operational Progress
finance.yahoo.com - August 1 at 6:49 PM |
| Edge Therapeutics reports 2Q loss
finance.yahoo.com - August 1 at 6:49 PM |
| -$0.45 Earnings Per Share Expected for Edge Therapeutics, Inc. (NASDAQ:EDGE) This Quarter
www.americanbankingnews.com - July 17 at 11:31 AM |
| Edge Therapeutics, Inc. (EDGE) Insider Sells $76,425.00 in Stock
www.americanbankingnews.com - July 6 at 8:05 PM |
| Zacks: Brokerages Anticipate Edge Therapeutics, Inc. (EDGE) Will Post Earnings of -$0.45 Per Share
www.americanbankingnews.com - June 21 at 7:34 AM |
| Edge Therapeutics to Participate in the JMP Securities Life Science Conference
finance.yahoo.com - June 15 at 6:57 PM |
| Edge Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
finance.yahoo.com - June 8 at 5:55 PM |
| Edge Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
finance.yahoo.com - June 8 at 5:55 PM |
 | European ADRs Edge Higher as Telecommunication Stocks Advance
www.nasdaq.com - May 12 at 5:22 PM |
| Edge Therapeutics Inc (EDGE) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 6 at 12:40 AM |
| Edge Therapeutics Inc (EDGE) Posts Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - May 6 at 12:17 AM |
| Edge Therapeutics Inc (EDGE) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - May 5 at 11:52 PM |
| Edge Therapeutics Inc (EDGE) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 2:30 PM |
| Leerink Swann Weighs in on Edge Therapeutics Inc's Q2 2017 Earnings (EDGE)
www.americanbankingnews.com - May 5 at 9:29 AM |
| Edited Transcript of EDGE earnings conference call or presentation 3-May-17 12:30pm GMT
finance.yahoo.com - May 4 at 11:43 AM |
| Edge Therapeutics (EDGE) Receiving Somewhat Positive Press Coverage, Report Finds
www.americanbankingnews.com - May 4 at 9:18 AM |
| BRIEF-Edge Therapeutics Qtrly loss per share $0.42
www.reuters.com - May 3 at 4:47 PM |
| Edge Therapeutics Reports First Quarter 2017 Financial Results and Continued Operational Progress
finance.yahoo.com - May 3 at 10:24 AM |
| Investor Network: Edge Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 10:24 AM |
 | Edge Therapeutics reports 1Q loss
marketbeat.com - May 3 at 6:42 AM |
| Zacks: Brokerages Anticipate Edge Therapeutics Inc (EDGE) to Announce -$0.42 EPS
www.americanbankingnews.com - May 2 at 8:00 PM |
| Edge Therapeutics (EDGE) Earns News Impact Score of 0.17
www.americanbankingnews.com - April 30 at 1:53 PM |
| Edge Therapeutics (EDGE) Receiving Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 27 at 10:56 PM |
| Short Interest in Edge Therapeutics Inc (EDGE) Increases By 6.4%
www.americanbankingnews.com - April 26 at 9:59 AM |
| Edge Therapeutics (EDGE) Earning Somewhat Critical Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 20 at 5:00 PM |
 | Edge Therapeutics (EDGE) Enters Agreement for $18M Registered Direct Offering of Common Stock
www.streetinsider.com - April 20 at 9:22 AM |
| BRIEF-Edge Therapeutics announces $18 mln registered direct offering of common stock
www.reuters.com - April 20 at 9:22 AM |
| Edge Therapeutics Announces $18 Million Registered Direct Offering of Common Stock
www.nasdaq.com - April 19 at 12:21 PM |
| Edge Therapeutics (EDGE) Earning Somewhat Negative Media Coverage, Report Shows
www.americanbankingnews.com - April 15 at 9:45 AM |
| Analysts Anticipate Edge Therapeutics Inc (EDGE) to Announce -$0.42 EPS
www.americanbankingnews.com - April 11 at 2:13 PM |
| Edge Therapeutics Inc (EDGE) Given $21.00 Consensus Target Price by Brokerages
www.americanbankingnews.com - April 6 at 8:04 AM |
 | Edge Therapeutics to Present at Needham & Company's 16th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 30 at 5:20 PM |
Edge Therapeutics (EDGE) Chart for Wednesday, September, 20, 2017
